CCL5 and acute myeloid leukemia: FLT3-internal tandem duplication (ITD)-mutated AML cell lines resistant to midostaurin, a tyrosine kinase inhibitor approved for the treatment of FLT3-mutant AML, secrete high levels of CCL5.